Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical leader specializing in dermatology treatments. This page aggregates official announcements and verified updates about DERM's prescription drug developments, financial performance, and regulatory progress.
Find categorized press releases covering FDA approvals, clinical trial results, partnership agreements, and earnings disclosures. Investors gain streamlined access to strategic updates impacting DERM's position in the $7.3B U.S. dermatology pharmaceuticals market.
Key resources include product launch timelines, research collaboration details, and analysis of DERM's branded/generic medication portfolio. Content is rigorously curated to support informed decision-making without promotional bias.
Bookmark this page for efficient tracking of DERM's advancements in treating acne, rosacea, and other skin conditions through FDA-cleared therapies.
Journey Medical , a pharmaceutical company specializing in dermatological products, will announce its first quarter 2024 financial results on May 13, 2024. The company will host a conference call to discuss the results and provide a corporate update at 4:30 p.m. ET on the same day.
Journey Medical has appointed Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Benesch brings over 25 years of experience in financial leadership and reporting, with a focus on the pharmaceutical industry. The company's Co-Founder, President, and CEO praised Benesch's expertise and contributions to the finance and accounting team, emphasizing his role in upcoming milestones like the potential approval of DFD-29 for rosacea treatment. Benesch's extensive background includes positions at Teligent Pharma Inc., Torrent Pharmaceuticals, Savient Pharmaceuticals, Adare Pharmaceuticals, and Edenbridge Pharmaceuticals, along with experience at Baker Tilly Virchow Krause, LLP, and Ernst and Young. With a BA in accounting and CPA certification from Wilkes University, Benesch aims to drive sustainable value for Journey Medical and its shareholders while supporting patients with dermatological products.
FAQ
What is the current stock price of Journey Medical (DERM)?
What is the market cap of Journey Medical (DERM)?
